View Older Stories View More Recent Stories

Feb 28, 2019 08:00AM AbbVie to Present at the Cowen Health Care Conference
Feb 25, 2019 08:32AM AbbVie (ABBV) to Showcase Scientific Innovation, Research Advancements Across Dermatology Portfolio at AAD
Feb 25, 2019 08:31AM AbbVie to Showcase Scientific Innovation and Research Advancements Across Dermatology Portfolio at 2019 AAD Annual Meeting
Feb 22, 2019 08:01AM AbbVie (ABBV), Voyager Therapeutics (VYGR) Enter Pact to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies
Feb 22, 2019 08:00AM AbbVie and Voyager Therapeutics Announce Collaboration to Develop Vectorized Antibodies to Treat Parkinson's Disease and Other Synucleinopathies
Feb 21, 2019 01:21PM AbbVie Declares Quarterly Dividend
Feb 19, 2019 08:37AM AbbVie (ABBV) Announces NDA Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe RA
Feb 19, 2019 08:31AM AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis
Feb 11, 2019 08:05AM AbbVie (ABBV), Teneobio Announce Pact to Develop a New Treatment for Multiple Myeloma
Feb 11, 2019 08:00AM AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma
Jan 28, 2019 07:01AM AbbVie (ABBV) Announces U.S. FDA Approval of IMBRUVICA Plus Obinutuzumab for CLL/SLL
Jan 28, 2019 07:00AM AbbVie Announces U.S. FDA Approval of IMBRUVICA® (ibrutinib) Plus Obinutuzumab (GAZYVA®) - First Chemotherapy-Free, Anti-CD20 Combination Regimen Approved for Chronic Lymphocytic Leukemia/Small Lymp
Jan 25, 2019 07:42AM AbbVie Reports Full-Year and Fourth-Quarter 2018 Financial Results
Jan 18, 2019 04:31PM AbbVie (ABBV) Phase 3 Study of Ibrutinib in Metastatic Pancreatic Did Not Meet its Primary Endpoint
Jan 18, 2019 04:29PM AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer
Jan 3, 2019 08:44AM AbbVie (ABBV), Tizona Therapeutics Report Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39
Jan 3, 2019 08:30AM AbbVie and Tizona Therapeutics Announce Strategic Collaboration to Develop First-in-Class Immunotherapy for Cancer Targeting CD39
Jan 3, 2019 08:00AM AbbVie to Host Fourth-Quarter and Full-Year 2018 Earnings Conference Call
Dec 24, 2018 09:42AM AbbVie (ABBV) to License Lupin's MALT1 Inhibitor Program to Develop & Commercialize Novel Oncology Drug to Treat Hematological Cancers
Dec 20, 2018 08:51AM AbbVie (ABBV) Submits NDA to U.S. FDA and MAA to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis
Dec 20, 2018 08:50AM AbbVie Submits New Drug Application to U.S. FDA and Marketing Authorization Application to EMA for Upadacitinib for Treatment of Adults with Moderate to Severe Rheumatoid Arthritis
Dec 20, 2018 08:00AM AbbVie to Present at the 37th Annual J.P. Morgan Healthcare Conference
Dec 17, 2018 09:00AM AbbVie Announces Executive Leadership Changes
Dec 13, 2018 01:00PM AbbVie (ABBV) Announces $5B Increase in Buyback Plan
Dec 13, 2018 01:00PM AbbVie Announces $5 Billion Increase to Stock Repurchase Program
Dec 11, 2018 08:14AM Symboli Security Token Offering (STO) Showcasing the First Cannabis Dividend®
Dec 5, 2018 04:47PM AbbVie (ABBV) Phase 3 Trial of Rova-T Halted After Shorter Overall Survival
Dec 5, 2018 04:01PM Phase 3 Trial of Rova-T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE STUDY) Halted
Dec 4, 2018 11:54AM AbbVie (ABBV) Says IMBRUVICA Combo Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR in Some CLL Patients
Dec 4, 2018 11:52AM IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic
Dec 3, 2018 02:27PM AbbVie (ABBV) IMBRUVICA Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement PFS Over Standard Chemoimmunotherapy for Previously Untreated CLL/SLL
Dec 3, 2018 02:17PM IMBRUVICA® (ibrutinib) Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab f
Dec 3, 2018 06:10AM AbbVie (ABBV) Reports New Data from Phase 3 MURANO Trial of VENCLEXTA/VENCLYXTO (venetoclax) in Combination with Rituximab
Dec 2, 2018 12:00PM IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a
Dec 1, 2018 05:47PM AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed
Nov 30, 2018 10:01AM Pfizer (PFE) Reaches Global Agreement with AbbVie (ABBV) on Adalimumab Biosimilar
Nov 30, 2018 10:00AM AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Pfizer
Nov 21, 2018 02:15PM AbbVie (ABBV) Receives US FDA Accelerated Approval for VENCLEXTA to Treat AML
Nov 21, 2018 02:14PM AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Nov 20, 2018 08:37AM AbbVie (ABBV) to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at ASH
Nov 20, 2018 08:32AM AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual M
Nov 15, 2018 03:00AM Mission Therapeutics and AbbVie Sign DUBs Collaboration in Alzheimer’s and Parkinson’s Disease
Nov 14, 2018 05:40PM AbbVie (ABBV) Presents Positive Phase 3 Data Showing Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at AAGL
Nov 14, 2018 05:35PM AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
Nov 13, 2018 11:31AM AbbVie (ABBV) Says MAVYRET Shows High Virologic Cure Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
Nov 13, 2018 11:30AM AbbVie's MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
Nov 13, 2018 08:00AM AbbVie to Present at the Evercore ISI Conference
Nov 9, 2018 08:00AM AbbVie Characterizes Evolving Hepatitis C (HCV) Patient Landscape in the United States Using Comprehensive Dataset
Nov 6, 2018 05:05PM AbbVie (ABBV) Announces HUMIRA Global Patent License with Momenta (MNTA)
Nov 6, 2018 04:45PM AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Momenta
View More Recent Stories View Older Stories